Indication
Axial Spondyloarthritis
23 clinical trials
28 products
1 drug
Clinical trial
A Randomized, Double-blinded, Phase II, Placebo-controlled Study to Evaluate the Safety and Efficacy of SCT650C in Participants With Axial SpondyloarthritisStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)Status: Not yet recruiting, Estimated PCD: 2025-11-30
Product
608Product
PlaceboProduct
SCT650CClinical trial
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axial Spondyloarthritis.Status: Active (not recruiting), Estimated PCD: 2024-04-08
Product
SecukinumabClinical trial
A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2026-08-07
Product
BimekizumabClinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial SpondyloarthritisStatus: Completed, Estimated PCD: 2020-08-14
Product
FilgotinibProduct
Standard of CareProduct
UpadacitinibClinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisStatus: Completed, Estimated PCD: 2022-06-29
Clinical trial
Effectiveness of Upadacitinib in Patients With Axial Spondyloarthritis Suffering From Typical Disease Activity and Pain in a Real-World SettingStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionStatus: Recruiting, Estimated PCD: 2030-04-24
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind, Parallel-group Program to Evaluate Efficacy and Safety of Filgotinib in Adult Subjects With Active Axial SpondyloarthritisStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR1501 Injection by in Patients With Active Axial SpondyloarthritisStatus: Completed, Estimated PCD: 2021-07-30
Product
IL-17A antibodyClinical trial
An International, Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
GR1501Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2024-11-10
Product
placeboProduct
secukinumabClinical trial
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence StudyStatus: Completed, Estimated PCD: 2021-12-31
Product
AdalimumabClinical trial
Pan-EU Real-World Experience With Imraldi®Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
TNFiClinical trial
Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation StudyStatus: Completed, Estimated PCD: 2024-03-01
Product
TofacitinibClinical trial
ToFAcitinib in Early Active Axial SpondyloarThritis: a Prospective, Randomized, Double-BLind, PlAcebo-CoNtrolled MulticEntre StudyStatus: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of BCD-180 in Patients With Active Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Optimization of Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17Status: Recruiting, Estimated PCD: 2026-12-01
Product
Anti-IL-17 therapyClinical trial
Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 TrialsStatus: Completed, Estimated PCD: 2023-08-11
Product
Drug order 1Product
Drug order 2Product
Drug order 3Product
LarazotideProduct
Drug order 5Product
ABT-089Clinical trial
RANDOMIZED DOUBLE BLIND CONTROLLED STUDY ASSESSING THE EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RESISTANT TO CONVENTIONAL TREATMENTStatus: Recruiting, Estimated PCD: 2027-09-01
Product
Active FMTDrug
VarlilumabClinical trial
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial SpondyloarthritisStatus: Recruiting, Estimated PCD: 2024-11-01
Product
TNF blockerProduct
Blood Specimen